Stroke Update 2011: New Antithrombotics.
- Author:
Kwon Duk SEO
1
;
Kyung Yul LEE
Author Information
1. Department of Neurology, Severance Institute for Vascular and Metabolic Research, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. kylee@yuhs.ac
- Publication Type:Clinical Trial ; Review
- Keywords:
Atrial fibrillation;
Anticoagulant;
Antiplatelet agent;
Ischemic stroke
- MeSH:
Aspirin;
Atrial Fibrillation;
Benzimidazoles;
beta-Alanine;
Factor Xa;
Humans;
Incidence;
Intracranial Hemorrhages;
Korea;
Lactones;
Morpholines;
Naphthalenes;
Propionates;
Pyrazoles;
Pyridines;
Pyridones;
Receptors, Thromboxane A2, Prostaglandin H2;
Stroke;
Thiophenes;
Thrombin;
Dabigatran;
Rivaroxaban
- From:Korean Journal of Stroke
2012;14(2):62-66
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Several new antithrombotic drugs have been developed and approved to use in clinical practice recently. Dabigatran, a direct thrombin inhibitor, and rivaroxaban, a factor Xa inhibitor, have been approved in many countries including Korea to prevent stroke in patient with atrial fibrillation. Apixaban, another factor Xa inhibitor, showed good results in clinical trial and is waiting for approval for clinical use. New antiplatelet agent, terutroban, selective thromboxane A2 receptor inhibitor, failed to prove the efficacy over the aspirin in secondary stroke prevention. Vorapaxar, a new antiplatelet agent that inhibits thrombin through PAR-1 antagonism, showed a high incidence of intracranial hemorrhage in patient with a history of stroke.
